Brief: Karyopharm Announces New Preliminary Data In Overall Survival In Selinexor-Treated Patients With Advanced Or Recurrent TP53 Wild-Type Endometrial Cancer

Karyopharm Therapeutics

06/11/2023 12:17

Nov 6 (Reuters) - Karyopharm Therapeutics Inc  KPTI.O :
    * KARYOPHARM ANNOUNCES NEW PRELIMINARY DATA IN OVERALL
SURVIVAL
(OS) IN SELINEXOR-TREATED PATIENTS WITH ADVANCED OR RECURRENT
TP53 WILD-TYPE ENDOMETRIAL CANCER AS PART OF PRE-SPECIFIED
EXPLORATORY SUBGROUP ANALYSIS OF THE SIENDO STUDY
    * KARYOPHARM THERAPEUTICS INC: MEDIAN OS NOT REACHED FOR
SELINEXOR-TREATED PATIENTS WHO ARE TP53 WILD-TYPE PMMR
    * KARYOPHARM: LONG-TERM SAFETY & EFFICACY DATA FROM SIENDO
STUDY
IN TP53 WILD-TYPE EXPLORATORY SUBGROUP SHOWED SIGNALS OF
IMPROVEMENT IN OS REGARDLESS OF MMR
    * KARYOPHARM THERAPEUTICS INC: TEAES LEADING TO
DISCONTINUATIONS
IN SELINEXOR GROUP WERE REPORTED IN 16% OF PATIENTS IN STUDY

Source text for Eikon:  ID:nPn8bvnPxa 
Further company coverage:  KPTI.O 

 ((Reuters.Briefs@thomsonreuters.com;))